Navigation Links
Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
Date:11/4/2008

BEIJING, Nov. 4 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it will present at the upcoming Rodman & Renshaw Global Investment Conference taking place from November 10 to 12, 2008 in New York City.

The date, time and location of Lotus Pharmaceuticals' presentation at the conference are:

Date: Tuesday, November 11, 2008

Time: 12:25 P.M. EST

Venue: Henry Salon, 5th Floor

The New York Palace Hotel

455 Madison Avenue

New York, NY 10022

This three day conference will feature presentations from more than 250 companies in the healthcare, steel, metals and mining and energy industries, with an "Asia & Growth" track. The Company's Chief Financial Officer will present at the conference. For more information about the conference, please view http://www.rodmanandrenshaw.com or E-mail lk@rodmanandrenshaw.com

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical Company, Ltd. ("Liang Fang") and En Ze Jia Shi Pharmaceutical Company, Ltd. ("En Ze"), two pharmaceutical companies located in Beijing, China. Together, Liang Fang and En Ze form an operating company (together, "Lotus East"). Lotus East engages in the development of new drugs, drug manufacturing, and the marketing and sales of pharmaceuticals. Lotus East has advanced pharmaceutical production equipment with which it produces a portfolio of pharmaceutical products, and meets National GMP. Lotus East has a number of highly skilled scientists, 2,000 square meters of office space and a 1,000 square meter warehouse. It operates ten retail pharmacies in the Beijing area.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K filed with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Phone: +1-877-801-0344

Email: info@LotusEast.com

Website: http://www.lotuseast.com

CCG Investor Relations Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Website: http://www.ccgir.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
2. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
3. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
4. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
5. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
6. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
7. Lotus Pharmaceuticals Raises $5 Million in Private Placement
8. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
9. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
10. Jazz Pharmaceuticals to Present at Investor Conferences
11. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: